← back to search

Yu Gu

AstraZeneca (United States) · CN
Area of research
Molecular Biology · Hematology
Research interest
Research interests include Acute Myeloid Leukemia Research, Epigenetics and DNA Methylation, Lipid metabolism and biosynthesis, and Metabolomics and Mass Spectrometry Studies.
h-index
27
citations
2,744
works
95
NIH funding
primary concept
Medicine
email

Recent publications

Menin Inhibition With Revumenib for <i>KMT2A</i> -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)
Journal of Clinical Oncology 2024cited by 169position: middledoi
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
Nature 2023cited by 450position: middledoi
m6A regulator-based methylation modification patterns and characterization of tumor microenvironment in acute myeloid leukemia
Frontiers in Genetics 2022cited by 12position: middledoi
SLC22A3 methylation-mediated gene silencing predicts adverse prognosis in acute myeloid leukemia
Clinical Epigenetics 2022cited by 7position: firstdoi
Genome-wide methylation sequencing identifies progression-related epigenetic drivers in myelodysplastic syndromes
Cell Death and Disease 2020cited by 38position: middledoi
Identification and validation of prognosis‐related <i>DLX5</i> methylation as an epigenetic driver in myeloid neoplasms
Clinical and Translational Medicine 2020cited by 36position: middledoi
Methylation-independent <i>CRIP1</i> expression is a potential biomarker affecting prognosis in cytogenetically normal acute myeloid leukemia.
PubMed 2020cited by 6position: middle
The M2 macrophage marker <i>CD206</i> : a novel prognostic indicator for acute myeloid leukemia
OncoImmunology 2019cited by 200position: middledoi
BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia
Diagnostic Pathology 2019cited by 80position: middledoi
MicroRNA-335/ID4 dysregulation predicts clinical outcome and facilitates leukemogenesis by activating PI3K/Akt signaling pathway in acute myeloid leukemia
Aging 2019cited by 29position: middledoi
Isocitrate dehydrogenase1 mutation reduces the pericyte coverage of microvessels in astrocytic tumours
Journal of Neuro-Oncology 2019cited by 20position: middledoi
Identification and validation of SRY-box containing gene family member SOX30 methylation as a prognostic and predictive biomarker in myeloid malignancies
Clinical Epigenetics 2018cited by 35position: middledoi
Measurements of Self-Efficacy in Patients with Chronic Kidney Disease: A Literature Review.
PubMed 2018cited by 7position: last
Cideb Deficiency Aggravates Dextran Sulfate Sodium-induced Ulcerative Colitis in Mice by Exacerbating the Oxidative Burden in Colonic Mucosa
Inflammatory Bowel Diseases 2017cited by 13position: middledoi
Ubiquitylation of Autophagy Receptor Optineurin by HACE1 Activates Selective Autophagy for Tumor Suppression
Cancer Cell 2014cited by 248position: middledoi
Architecture of Human Translation Initiation Factor 3
Structure 2013cited by 72position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Jiang Lin · Fudan University8 papers (2018–2022)Ji‐chun Ma · Jiangsu University7 papers (2018–2022)Xiang‐mei Wen · Jiangsu University7 papers (2019–2022)Jing‐dong Zhou · Jiangsu University7 papers (2018–2022)Ting‐juan Zhang · Jiangsu University6 papers (2018–2020)Jun Qian · Northwestern University5 papers (2018–2020)Zhaoqun Deng · Jiangsu University4 papers (2019–2020)Jun Qian · Fudan University3 papers (2019–2022)Cuizhu Wang · Nantong University2 papers (2019–2020)Jing Ye · New York University2 papers (2017–2019)Chao Wang · National University of Singapore2 papers (2017–2019)Zhe Wang · Wenzhou Medical University2 papers (2017–2019)Wei Zhang · University of Illinois Chicago2 papers (2019–2020)Chao Sun · Xuzhou Medical College2 papers (2017–2019)Zhuyi Li · Nantong University2 papers (2017–2019) · 2 papers (2017–2019) · 2 papers (2017–2019)Lei Yang · Gansu Provincial Maternal and Child Health Hospital2 papers (2019–2022)Pei‐hui Xia · Jiangsu University2 papers (2022–2022)Xing Gao · Fudan University2 papers (2017–2019)